Willemze R, Assaf C, Bagot M, Beylot-Barry M, Berti E, Busschots AM, Cerroni L, Climent F, Diercks G, Geskin L, Gniadecki R, Gru AA, Guenova E, Guitart J, Jansen P, Kempf W, Kim E, Kim YH, Koldijk M, Marschalkó M, Mitteldorf C, Molgó M, Muniesa C, KJ Neelis, Olsen E, Ortiz-Romer PLo, Papadavid E, Pimpinelli N, Pulitzer M, Quaglino P, Querfeld C, Quint K, Scarisbrick JS, Schrader AMR, Stadler R, Vermeer M, Wehkamp U, Whittaker S, Wobser M. European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders. , Br J Dermatol, 193(6): 2025,1090-1100
Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM. Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study.
Journal of the American Academy of Dermatology 2025-05-01 , J Am Acad Dermatol., 92(5): 2025,1100-1102
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol., 92(3): 2025,634-636
Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome , JAMA Dermatol, 161(6): 2025,656-658
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol: 2024
Villasenor-Park J, Chung J, Kim EJ Cutaneous B-cell Lymphomas/Cutaneous Oncology , Hematology Oncology Clinics, 38(5): 2024,1111
Silva GS, Kim EJ, Barta SK, Chung J Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature , Expert Rev Anticancer Ther, 24(9): 2024,819-827
Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma.
, International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C.: 2024
Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies
, Transplant Cell Ther, 24: 2024
Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK. Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma , Dermatologic Therapy: 2023
